Literature DB >> 18326719

Acute endothelin-1 application induces reversible fast axonal transport blockade in adult rat optic nerve.

Xu Wang1, William H Baldridge, Balwantray C Chauhan.   

Abstract

PURPOSE: To investigate the effects of endothelin (ET)-1 on fast axonal transport in the optic nerve.
METHODS: Sterile sponge soaked in 1 nM ET-1 was applied to the optic nerve surface of adult Brown Norway rats for 1 hour, after which 20% horseradish peroxidase (HRP) was placed over the superior colliculi (SC). Rats were killed 2, 4, 6, 24, and 48 hours later; the retinas and optic nerves were removed and fixed; and cut sections were processed histochemically, to visualize the time course of HRP transport by light microscopy. Naive and saline controls were processed identically. Retinal ganglion cell (RGC) survival after acute ET-1 application was investigated in another group of animals. After retrograde labeling of RGCs with the fluorescent neurotracer Fluorochrome (FG; Fluorogold; Fluorochrome Inc., Denver, CO), 1 nM ET-1 was applied to the optic nerve. Rats were then killed 5, 10, and 21 days later. The retinas were whole mounted and FG-positive RGCs were imaged and quantified with fluorescence microscopy.
RESULTS: In naive controls, HRP labeling was observed over the entire nerve at 2 hours but had cleared by 48 hours. HRP labeling of RGCs started at 6 hours, and by 48 hours, uniform labeling was seen throughout the retina. In ET-1-treated optic nerves, transport of HRP was arrested at the distal portion of the nerve at 2 hours. Recovery of transport was evident from 4 hours. At 6 and 24 hours, all nerves showed full recovery with HRP-positive RGCs in the retina, but the ratio of the RGC counts in treated versus fellow untreated eyes (0.66 +/- 0.13 and 0.67 +/- 0.17, respectively) was less than that of the naive control (1.02 +/- 0.28 and 1.05 +/- 0.13, respectively) animals. At 48 hours, recovery was complete, and there was no significant difference in the ratio of RGC counts between ET-1 and naive control groups. No RGC loss was observed after ET-1 application.
CONCLUSIONS: Local acute application of ET-1 produces a reversible blockade of rapid axonal transport in optic nerve.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 18326719     DOI: 10.1167/iovs.07-1243

Source DB:  PubMed          Journal:  Invest Ophthalmol Vis Sci        ISSN: 0146-0404            Impact factor:   4.799


  8 in total

Review 1.  A biomechanical paradigm for axonal insult within the optic nerve head in aging and glaucoma.

Authors:  Claude F Burgoyne
Journal:  Exp Eye Res       Date:  2010-09-16       Impact factor: 3.467

Review 2.  Differential gene expression in glaucoma.

Authors:  Tatjana C Jakobs
Journal:  Cold Spring Harb Perspect Med       Date:  2014-07-01       Impact factor: 6.915

Review 3.  Critical pathogenic events underlying progression of neurodegeneration in glaucoma.

Authors:  David J Calkins
Journal:  Prog Retin Eye Res       Date:  2012-08-01       Impact factor: 21.198

Review 4.  Inducible rodent models of glaucoma.

Authors:  Iok-Hou Pang; Abbot F Clark
Journal:  Prog Retin Eye Res       Date:  2019-09-23       Impact factor: 21.198

5.  Bevacizumab therapy normalizes the pathological intraocular environment beyond neutralizing VEGF.

Authors:  Rajesh K Sharma; Anna T Rogojina; K V Chalam
Journal:  Mol Vis       Date:  2010-10-27       Impact factor: 2.367

6.  In Vivo Small Molecule Delivery to the Optic Nerve in a Rodent Model.

Authors:  Shandiz Tehrani; R Katherine Delf; William O Cepurna; Lauren Davis; Elaine C Johnson; John C Morrison
Journal:  Sci Rep       Date:  2018-03-13       Impact factor: 4.379

7.  Axonal Transport as an In Vivo Biomarker for Retinal Neuropathy.

Authors:  Lucia G Le Roux; Xudong Qiu; Megan C Jacobsen; Mark D Pagel; Seth T Gammon; David R Piwnica-Worms; Dawid Schellingerhout
Journal:  Cells       Date:  2020-05-22       Impact factor: 6.600

8.  Multiplex immunoassay analysis of biomarkers in clinically accessible quantities of human aqueous humor.

Authors:  Rajesh K Sharma; Anna T Rogojina; K V Chalam
Journal:  Mol Vis       Date:  2009-01-14       Impact factor: 2.367

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.